|
|
|
|
|
|
|
|
|
Monday June 27, 2005
|
|
7:15 am
|
|
|
8:15 am
|
Occupational asthma is the most prevalent form of occupational lung disease in industrialized nations. As increasing numbers of new chemicals are produced and new manufacturing processes are introduced, the variety of environments in which individuals may become exposed to respiratory sensitizers and irritants makes diagnosing and treating this illness even more challenging. In addition to adverse pulmonary effects, the diagnosis of occupational asthma may bring with it negative social and financial implications that may ultimately affect the patient's quality of life and increase the employer's costs of care. For this reason, it is important for health care professionals and workplace supervisors to recognize work-related respiratory symptoms early on in their course, focus on preventing workplace exposures and subsequent aggravations.
- Review the current clinical aspects of occupational/environmental asthma
- Recognize programmatic resources and strategies for preventing work-related respiratory illness
- Determine how cost-saving and effective programs for prevention and rapid response can be implemented in a "real world" setting
|
|
|
|
|
10:00 am
|
|
|
11:30 am
|
|
|
11:30 am
|
|
|
Clayton T. Cowl
MD, FCCP
Division of Preventive & Occupational Medicine
Division of Pulmonary & Critical Care Medicine
Mayo Clinic
|
| Dr. Clayton Cowl is the Coordinator of Mayo Clinic's Occupational Respiratory Clinic in Rochester, Minnesota. He is board-certified in both Pulmonary & Critical Care Medicine, and in Occupational Medicine, currently serving as the Chair of the Occupational/Environmental Medicine NetWork for the American College of Chest Physicians. Dr. Cowl's research interests include occupational asthma, occupationally-related interstitial lung disease, and altitude physiology. He also serves as the Chief of the Section of Aerospace Medicine at Mayo Clinic. |
|
Katherine Sarlo
PhD
Principal Scientist
Central Product Safety Organization
Procter & Gamble Company
|
| Katherine Sarlo, Ph.D., joined the Procter & Gamble Company in 1985 and is a Principal Scientist in the Central Product Safety Organization. Dr. Sarlo directs both internal and external pre-clinical and clinical research in the area of type 1 allergy to proteins. She is also responsible for developing approaches to risk assessment that incorporate exposure and outcome as it relates to type 1 allergy. Dr. Sarlo has presented her research at numerous scientific meetings over the years and much of the work has been published in peer reviewed scientific journals. Dr. Sarlo has served as an expert consultant to various organizations (WHO, EPA, ILSI, SDA, ECETOC) charged with assessing the state of the science in type 1 allergy. Dr. Sarlo received a BS in Biology at the State University of New York at Stony Brook in 1980 and her PhD in Microbiology/Immunology at the Ohio State University in 1985. |
|
David Weissman
MD, FCCP
Director, Respiratory Disease Studies
National Institute of Occupational Safety and Health
|
| David N. Weissman, M.D., holds the position of Director, Division of Respiratory Disease Studies, National Institute for Occupational Safety and Health, Morgantown, WV. He is a graduate of Northwestern University in Chicago, Illinois, where he earned his M.D. in 1978. He did his internal medicine internship at Michael Reese Hospital and Medical Center in Chicago and completed residency training in internal medicine and fellowship training in Pulmonary Diseases and Allergy-Immunology, at Tulane University New Orleans, LA. He subsequently held faculty positions at the University of New Mexico, West Virginia University, and NIOSH, where his research has focused on occupational and immunemediated respiratory diseases. Dr. Weissman is a diplomate of the American Board of Internal Medicine (1982), the American Board of Allergy and Immunology (1985), and the American Board of Internal Medicine, Subspecialty in Pulmonary Diseases (1986). |
|
|
|
|
|
|
|
|
 |
|
|